NZ756412B2 - Combination treating prostate cancer, pharmaceutical composition and treatment method - Google Patents

Abstract

Disclosed are a combination treating prostate cancer, a pharmaceutical composition and a treatment method. The combination includes one of a benzoheterocyclic compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, a crystalline form thereof, a co-crystal thereof, a stereoisomer thereof, an isotope compound thereof, a metabolite thereof and a prodrug thereof, and an androgen receptor pathway modulator. The combination, the pharmaceutical composition thereof and the treatment method inhibit prostate cancer in a more effective manner. reof, a stereoisomer thereof, an isotope compound thereof, a metabolite thereof and a prodrug thereof, and an androgen receptor pathway modulator. The combination, the pharmaceutical composition thereof and the treatment method inhibit prostate cancer in a more effective manner.

Description

Combination Treating te Cancer, Pharmaceutical Composition and Treatment Method Field of invention The present invention relates to a combination for the treatment of prostate cancer, a ceutical composition and a treatment method.

Prior arts Prostate cancer is a common malignancy in the male reproductive system. The statistics which was made by the International Agency for Research on Cancer of World Health Organization in 2012 showed that the number of newly diagnosed prostate cancer patients in the world was 1.1 n in that year, accounting for about 15% of the total number of new cancer cases, making it the second most common cancer in men worldwide. In the United States, the incidence of prostate cancer ranks first in all malignancies, with the second t mortality rate, second only to lung cancer. Although the incidence of prostate cancer in China is much lower than that in western countries, it has shown a significant growth trend in recent years and ranks first among male urological tumors, and most of prostate cancer were sed in the terminal stage.

The growth of the prostate cancer cells requires the ting of androgens including testosterone. Therefore, the targeted treatment strategies for prostate cancer mainly focus on the synthesis of androgen and the binding to the en receptor thereof. For example, Enzalutamide, a prostate cancer drug marketed by the U.S. FDA in August 2012, is a small molecule androgen receptor nist, which finally inhibits the androgen receptor pathway by competitive inhibition of the binding of androgen to its receptor, thereby achieving the effect of treating tion-resistant prostate cancer.

Enzalutamide also shows some side effects in al studies, such as weakness or fatigue, lumbago, diarrhea, joint pain, hot s, tissue swelling, musculoskeletal pain, headache, upper respiratory tract infection, dizziness, spinal cord compression and cauda equina syndrome, muscle weakness, dyscoimesis, lower respiratory tract infection, hematuria, tingling, anxiety and hypertension and so on.

For the treatment of cancer, the drug combination is often used in the al practice to e the treatment effect, for example, the ation of docetaxel and prednisone for use in the treatment of prostate cancer. However, people have met great setbacks when exploring new composition regimens. One of the typical examples is that although the composition of docetaxel and prednisone can treat prostate cancer (Tannock et al. N. Eng. J. Med. (2004), 351, 1502-1512), the combination regimen of docetaxel, prednisone and lenalidomide failed in a Phase III al trial involving more than 1000 te cancer patients (Petrylak et al. Lancet Oncol. (2015) 16-4, 417-425). It should also be noted that, the results of l phase II clinical s also indicated that the clinical efficacy of lenalidomide alone in the treatment of prostate cancer was not satisfying (Xing et al. Asian Pac. J. Cancer Prev. (2015) 16- 9, 3969-3972).

Therefore, it has become an urgent technical problem to be solved in the art to explore composition regimens of anti-prostate cancer drugs (including Enzalutamide etc.) to improve the efficacy and reduce the toxic and side effect.

Content of the present invention The present ion provides a combination for the treatment of prostate cancer, a pharmaceutical composition and a treatment method. The combination for the treatment of prostate cancer, the pharmaceutical composition and the treatment method of the invention inhibit prostate cancer in a more effective manner.

The present invention provides a combination for the treatment of prostate , comprising one of the benzoheterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope compound, metabolite and prodrug thereof, and the androgen receptor pathway modulator; in formula(I), n1 is 0 or 1; L1 and L3 are independently , CH2, CHD, CD2, , , or ; L2 is CD2, CHD or CH2； X is NH, ND or O； R1, R2 and R3 are independently H or D； Z is ; wherein, R4 is H, D, CH3, CH2D, CHD2 or CD3; R5, R6, R7, R8 and R9 are independently H or D; the carbon marked with * is an tric center; R10 is H, D or , n, R1’, R2’, R3’, R4’ and R5’ are independently selected from H, D, substituted or unsubstituted (C1-C12) alkyl; the substituent in the substituted (C1-C12) alkyl is selected from one or more of the following groups: D, (C2-C20) heterocycloalkyl, deuterated (C2-C20) heterocycloalkyl, (C2-C20) heterocycloalkyl substituted by 2) alkyl and (C2-C20) heterocycloalkyl substituted by deuterated (C1-C12) alkyl; when there are a plurality of substituents in the substituted (C1-C12) alkyl, the tuents are the same or ent; the heteroatom contained in the (C2-C20) heterocycloalkyl which is referred in the (C2-C20) heterocycloalkyl, deuterated (C2-C20) heterocycloalkyl, (C2-C20) heterocycloalkyl substituted by (C1-C12) alkyl and (C2-C20) heterocycloalkyl substituted by deuterated (C1-C12) alkyl is selected from one or more of O, N and S; in the formula (I), when n1 is 0, X is NH or ND, L1 is , CH2, CHD or CD2；L3 is ，then R10 is H or D; in the formula (I), when n1 is 0, X is NH or ND, L1 is , and L3 is , , or , then R10 is H or D; in the formula (I), when n1 is 1, L1 is CH2, CHD or CD2，L3 is ，then R10 is D represents deuterium-enriched en, and H represents uterium-enriched hydrogen; the androgen receptor pathway modulator is selected from: O O O NC CD3 NC N CD3 S NC CD3 S N N S N H H H F3C NN F F3C NN F F3C NN F O O O AR1-1 AR1-2 AR1-3 O O NC NC N D CD3 NC S N S N S N H H H F3C NN F O NN F F3C NN F D F O O O AR1-4 AR2-1 AR2-2 NC N S NC S CN NC O F3C NN F F3C NN F N N F3C NN F F F O O O AR2-3 AR2-4 AR2-5 O H NC NC N S NC NH2 S NH S O O F3C NN F F3C NN F3C NN F F F O O O AR2-6 AR2-7 AR2-8 H H H NC N S NC O N NC N S S O O O F3C NN F3C NN Cl NN F F F O O O AR2-9 AR2-10 AR2-11 NC NC NC S CN S CN S CN F3C NN F Cl NN F O NN F F F F O O O AR2-12 AR2-13 AR2-14 S NC N NC CN S S CN O NN F F3C NN O F3C NN F F F O O O AR2-15 AR2-16 AR2-17 NC NC NC N S CN S CN S F3C NN O Cl NN F3C NN F F F F O O O AR2-18 AR2-19 AR2-20 OH N NC O S NC N NC N S N S F3C NN F F3C NN F O F3C NN F O F F F O O O AR2-21 AR2-22 AR2-23 NC S N NC N NC S S O F3C NN N F3C NN F O N N F F3C NN F F O O O AR2-24 AR2-25 AR2-26 NC OH S S NC S O NH2 NC S O OH N N F3C NN F3C NN F F3C NN F O O O AR2-27 AR3-1 AR3-2 NC NC O OH S O OH S OH NC O F3C NN F3C NN F3C NN F O O O O AR3-3 AR3-4 AR3-5 NC O NC O NC O OH S S S F3C NN F3C NN O F3C NN O O O O AR3-6 AR3-7 AR3-8 NC S O OH F3C NN AR3-9 .

In the formula (I) of the present invention, the asymmetric center ably refers to (S)- configured carbon, (R)-configured carbon or racemate.

In the formula (I) of the present invention, the Z is preferably any one of the following structures: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ；Z is more preferably or ； n, the carbon marked with * is an asymmetric center, and the asymmetric center, H and D are defined as described above.

In the formula(I), the (C2-C20) heterocycloalkyl in the (C2-C20) heterocycloalkyl, the deuterated (C2-C20) heterocycloalkyl, the (C2-C20) cycloalkyl substituted by (C1-C12) alkyl, the (C2-C20) cycloalkyl substituted by deuterated (C1-C12) alkyl, is preferably a (C2-C6) heterocycloalkyl wherein the heteroatom is N or O and the number of heteroatoms is 1-2. The (C2-C6) heterocycloalky is ably a morpholinyl (e.g. ). The (C1-C12) alkyl in the (C2-C20) heterocycloalkyl substituted by (C1-C12) alkyl or the (C2-C20) cycloalkyl substituted by deuterated (C1-C12) alkyl is preferably a (C1-C4) alkyl. The (C1-C4) alkyl is preferably a methyl, an ethyl, a n-propyl, an isopropyl, a n-butyl, an isobutyl, or a tertiary-butyl.

In the formula(I), the substituted or unsubstituted (C1-C12) alkyl is preferably a substituted or unsubstituted ) alkyl. The substituted or unsubstituted (C1-C4) alkyl is preferably a substituted or unsubstituted methyl, a substituted or unsubstituted ethyl, a substituted or unsubstituted n-propyl, a substituted or unsubstituted isopropyl, a tuted or unsubstituted nbutyl , a substituted or unsubstituted yl, or a substituted or unsubstituted tertiary-butyl. The substituted (C1-C4) alkyl is preferably , , or .

In the formula(I), the is preferably , , , or .

The eterocyclic compound of formula(I) is preferably any one of the following compounds: O O O H O O N O O O H NH H NH H NH NH2 O H N O N O N O N N O O NH2 NH2 O N B001 F001 K001 D108 O O O O H NH O O O H NH D NH N O D NH N O N O N O NH2 NH2 D B002 B003 NH2 B004 B005 O O O O O O H NH O D NH NH O H NH N O N O N O N O D D D D NH2 NH2 NH2 D B006 B007 B008 F002 H H O O H O N O O N O O O O N O NH2 O NH2 O D NH NH2 O D D D NH H N O N O N N N NH2 O N N N F003 NH2 O F004 K002 K003 K004 H H O N O H O N O H NH2 O O N O NH2 O O N O H NH2 O D NH2 O H D N N N N N CD3 N CD3 N CD3 N CD3 K005 K006 K007 K008 D NH O O O H NH N O O N O N D NH N N O O O O O N D109 O O D110 D111 O O O O O O H NH D NH H NH N O N O N O N N N O O D D O O D D O O D D D112 D113 D114 O O O O D NH H NH O O N O N O H NH N O N N N O O D D O O D116 O O D117 D115 D D D D O O O O D NH H NH H NH N O N O N O N N N O O D D O O D D O O D118 D119 D120 D D D D D D O O D NH D NH N O N O N N O O O O D121 D D D D D122 D NH N O O O D D D D D123 。 In the combination of the invention, ably, the eterocyclic compound of formula(I) is selected from B001, F001, K001 or D108.

In the combination of the invention, preferably, the androgen receptor pathway tor is any one of the ing compounds: AR1-1, AR1-2, AR2-1, AR2-2, AR2-3, AR2-4, AR2-5, AR3-1, AR3-2, AR3-3, AR3-4.

In some embodiments of the invention, the combination preferably comprises the benzoheterocyclic compound of formula(I) and the androgen receptor pathway modulator, wherein, the benzoheterocyclic compound of formula(I) is selected from B001, F001, K001or D108; the androgen receptor pathway modulator is selected from one of the AR1-1, AR1-2, AR1- 3, AR1-4, AR2-1, AR2-2, AR2-3, AR2-4, AR2-5, AR2-6, AR2-7, AR2-8, AR2-9, AR2-10, AR2- 11, AR2-12, AR2-13, AR2-14, AR2-15, AR2-16, AR2-17, AR2-18, AR2-19, AR2-20, AR2-21, AR2-22, AR2-23, AR2-24, AR2-25, AR2-26, AR2-27, AR3-1, AR3-2, AR3-3, AR3-4, AR3-5, AR3-6, AR3-7, AR3-8and AR3-9; the androgen receptor pathway modulator is preferably selected from one of the AR1-1, AR1-2, AR2-1, AR2-2, AR2-3, AR2-4, AR2-5, AR3-1, AR3-2, AR3-3 and AR3-4.

In some ments of the invention, the combination is preferably any one of the following combinations: “B001 or F001 or K001 or D108” and AR1 -1, “B001 or F001 or K001 or D108” and AR1-2, “B001 or F001 or K001 or D108” and AR1-3, “B001 or F001 or K001 or D108” and AR1-4, “B001 or F001 or K001 or D108” and AR2-1, “B001 or F001 or K001 or D108” and AR2-2, “B001 or F001 or K001 or D108” and AR2-3, “B001 or F001 or K001 or D108” and AR2-4, “B001 or F001 or K001 or D108” and AR2-5, “B001 or F001 or K001 or D108” and AR2-6, “B001 or F001 or K001 or D108” and AR2-7, “B001 or F001 or K001 or D108” and AR2-8, “B001 or F001 or K001 or D108” and AR2-9, “B001 or F001 or K001 or D108” and AR2-10, “B001 or F001 or K001 or D108” and AR2-1 1, “B001 or F001 or K001 or D108” and AR2-12, “B001 or F001 or K001 or D108” and AR2-13, “B001 or F001 or K001 or D108” and AR2-14, “B001 or F001 or K001 or D108” an d AR2-15, “B001 or F001 or K001 or D108” and AR2-16, “B001 or F001 or K001 or D10 8” and , “B001 or F001 or K001 or D108” and AR2-18, “B001 or F001 or K001 or D108” and AR2-19, “B001 or F001 or K001 or D108” and AR2-20, “B001 or F001 or K0 01 or D108” and AR2- 21, “B001 or F001 or K001 or D108” and , “B001 or F001 or K001 or D108” and AR2-23, “B001 or F001 or K001 or D108” and AR2-24, “B001 or F0 01 or K001 or D108” and AR2-25, “B001 or F001 or K001 or D108” and AR2-26, “B001 or F001 or K001 or D108” and AR2-27, “B001 or F001 or K001 or D108” and AR3-1, “ B001 or F001 or K001 or D108” and AR3-2, “B001 or F001 or K001 or D108” and AR3-3, “B001 or F001 or K001 or D108” and AR3-4, “B001 or F001 or K001 or D108” and AR3-5, “B001 or F001 or K001 or D108” and AR3-6, “B001 or F001 or K001 or D108” and AR3-7, “B001 or F001 or K001 or D108” and AR3-8, “B001 or F001 or K001 or D108” and AR3-9.

The combination above, illustrated by the combination of "B001 or F001 or K001 or D108" and AR1-1, represents the combination of B001 and AR1-1, the combination of F001 and AR1- 1, the combination of K001 and AR1-1, and, the combination of D108 and AR1-1. According to this explanation, one skilled in the art can understand the meanings of the other ations mentioned above.

The combination of the invention may further comprise an other therapeutic agents selected from one of Abiraterone, Abiraterone acetate, Galeterone, ODM201, Prednisone, Abiraterone and sone, Abiraterone acetate and Prednisone, Galeterone and Prednisone, and, ODM201 and Prednisone. ore, the combination of the invention preferably comprises the benzoheterocyclic compound of formula(I), the androgen receptor pathway modulator and the other therapeutic agent, wherein, the benzoheterocyclic compound of a(I) is selected from B001, F001, K001 or D108; the androgen receptor pathway modulator is selected from one of the AR1-1, AR1-2, AR1-3, AR1-4, AR2-1, AR2-2, AR2-3, AR2-4, AR2-5, AR2-6, AR2-7, AR2-8, AR2-9, AR2-10, AR2-11, AR2-12, , AR2-14, AR2-15, , AR2-17, AR2-18, AR2-19, AR2-20, AR2-21, AR2-22, AR2-23, , AR2-25, AR2-26, AR2-27, AR3-1, AR3-2, AR3- 3, AR3-4, AR3-5, AR3-6, AR3-7, AR3-8 and AR3-9; the androgen or pathway tor is preferably selected from one of the AR1-1, AR1-2, AR2-1, AR2-2, AR2-3, AR2-4, AR2-5, AR3-1, AR3-2, AR3-3, AR3-4; the other therapeutic agent is selected from one of Abiraterone, Abiraterone acetate, Galeterone, ODM201, Prednisone, erone and Prednisone, Abiraterone acetate and Prednisone, Galeterone and Prednisone, and, ODM201 and Prednisone.

In some embodiments of the invention, the combination is preferably any one of the following combinations: “B001 or F001 or K001 or D108” and AR1- 1 and Abiraterone, “B001 or F001 or K001 or D108” and AR1-2 and Abiraterone, “B001 or F0 01 or K001 or D108” and AR2-1 and Abiraterone, “B001 or F001 or K001 or D108” and AR2-2 and Abiraterone, “B001 or F001 or K001 or D108” and AR2-3 and Abiraterone, “B001 or F0 01 or K001 or D108” and AR2-4 and Abiraterone, “B001 or F001 or K001 or D108” and AR2-5 and Abiraterone, “B001 or F001 or K001 or D108” and AR3-1 and Abiraterone, “B001 or F0 01 or K001 or D108” and AR3-2 and erone, “B001 or F001 or K001 or D108” and AR3-3 and Abiraterone, “B001 or F001 or K001 or D108” and AR3-4 and Abiraterone, “B001 or F0 01 or K001 or D108” and AR1-1 and Abiraterone e, “B001 or F001 or K001 or D108” and AR1-2 and Abiraterone acetate, “B001 or F001 or K001 or D108” and AR2-1 and Abiratero ne acetate, “B001 or F001 or K001 or D108” and AR2-2 and Abiraterone acetate, “B001 or F0 01 or K001 or D108” and AR2-3 and Abiraterone acetate, “B001 or F001 or K001 or D108” and AR2-4 and Abiraterone acetate, “B001 or F001 or K001 or D108” and AR2-5 and Abiratero ne acetate, “B001 or F001 or K001 or D108” and AR3-1 and Abiraterone acetate, “B001 or F0 01 or K001 or D108” and AR3-2 and Abiraterone acetate, “B001 or F001 or K001 or D108” and AR3-3 and Abiraterone acetate, “B001 or F001 or K001 or D108” and AR3-4 and Abiratero ne acetate, “B001 or F001 or K001 or D108” and AR1-1 and rone, “B001 or F001 or K00 1 or D108” and AR1-2 and Galeterone, “B001 or F001 or K001 or D108” and AR2-1 and Galete rone, “B001 or F001 or K001 or D108” and AR2-2 and Galeterone, “B001 or F001 or K001 o r D108” and AR2-3 and Galeterone, “B001 or F001 or K001 or D108” and AR2-4 and Galete rone, “B001 or F001 or K001 or D108” and AR2-5 and Galeterone, “B001 or F001 or K001 o r D108” and AR3-1 and Galeterone, “B001 or F001 or K001 or D108” and AR3-2 and Galete rone, “B001 or F001 or K001 or D108” and AR3-3 and rone, “B001 or F001 or K001 o r D108” and AR3-4 and Galeterone, “B001 or F001 or K001 or D108” and AR1-1 and ODM201 , “B001 or F001 or K001 or D108” and AR1-2 and ODM201, “B001 or F001 or K001 or D108” a nd AR2-1 and ODM201, “B001 or F001 or K001 or D108” and AR2-2 and ODM201, “B001 or F 001 or K001 or D108” and AR2-3 and ODM201, “B001 or F001 or K001 or D108” and AR2-4 and ODM201, “B001 or F001 or K001 or D108” and AR2-5 and ODM201, “B001 or F001 or K001 or D108” and AR3-1 and ODM201, “B001 or F001 or K001 or D108” and AR3-2 and ODM201, “B001 or F001 or K001 or D108” and AR3-3 and ODM201, “B001 or F001 or K0 01 or D108” and AR3- 4 and , “B001 or F001 or K001 or D108” and AR1-1 and Pred nisone, “B001 or F001 or K001 or D108” and AR1-2 and Prednisone, “B001 or F001 or K00 1 or D108” and AR2-1 and Prednisone, “B001 or F001 or K001 or D108” and AR2-2 and Predni sone, “B001 or F001 or K001 or D108” and AR2-3 and Prednisone, “B001 or F001 or K001 o r D108” and AR2-4 and Prednisone, “B001 or F001 or K001 or D108” and AR2-5 and Predni sone, “B001 or F001 or K001 or D108” and AR3-1 and Prednisone, “B001 or F001 or K001 o r D108” and AR3-2 and Prednisone, “B001 or F001 or K001 or D108” and AR3-3 and Predni sone, “B001 or F001 or K001 or D108” and AR3-4 and Prednisone, “B001 or F001 or K001 o r D108” and AR1-1 and Abiraterone and Prednisone, “B 001 or F001 or K001 or D108” and AR1-2 and erone and Prednisone, “B001 or F001 or K001 or D108” and AR2-1 and Abirat erone and Prednisone, “B001 or F001 or K001 or D108” and AR2-2 and Abiraterone and Prednisone, “B001 or F001 or K001 or D108” and AR2-3 and Abiraterone and Prednisone, “B00 1 or F001 or K001 or D108” and AR2-4 and Abiraterone and Prednisone, “B001 or F001 or K001 or D108” and AR2-5 and Abiraterone and Prednisone, “B 001 or F001 or K001 or D108” and AR3-1 and Abiraterone and Prednisone, “B001 or F001 or K001 or D108” and AR3-2 and Abirat erone and Prednisone, “B001 or F001 or K001 or D108” and AR3-3 and Abiraterone and Prednisone, “B001 or F001 or K001 or D108” and AR3-4 and Abiraterone and Prednisone, “B00 1 or F001 or K001 or D108” and AR1-1 and Abiraterone e and Prednisone, “B001 or F001 or K001 or D108” and AR1- 2 and Abiraterone acetate and Prednisone, “B001 or F001 or K001 or D108” and AR2-1 and Abiraterone acetate and Prednisone, “B001 or F001 or K001 or D1 08” and AR2-2 and Abiraterone acetate and Prednisone, “B001 or F001 or K001 or D1 08” and AR2-3 and Abiraterone acetate and Prednisone, “B001 or F001 or K001 or D1 08” and AR2-4 and erone acetate and Prednisone, “B001 or F001 or K001 or D1 08” and AR2-5 and Abiraterone acetate and Prednisone, “B001 or F001 or K001 or D1 08” and AR3-1 and Abiraterone acetate and Prednisone, “B001 or F001 or K001 or D1 08” and AR3-2 and Abiraterone acetate and Prednisone, “B001 or F001 or K001 or D1 08” and AR3-3 and Abiraterone acetate and Prednisone, “B001 or F001 or K001 or D1 08” and AR3-4 and erone acetate and Prednisone, “B001 or F001 or K001 or D1 08” and AR1-1 and Galeterone and Prednisone, “B001 or F001 or K001 or D108” and A R1-2 and Galeterone and Prednisone, “B001 or F001 or K001 or D108” and AR2-1 and Galete rone and Prednisone, “B001 or F001 or K001 or D108” and AR2-2 and Galeterone and Prednisone, “B001 or F001 or K001 or D108” and AR2-3 and Galeterone and sone, “B001 or F001 or K001 or D108” and AR2-4 and Galeterone and Prednisone, ”B001 or F001 or K001 or D 108” and AR2-5 and Galeterone and sone, “B001 or F001 or K001 or D108” and A R3-1 and Galeterone and Prednisone, “B001 or F001 or K001 or D108” and AR3-2 and Galete rone and Prednisone, “B001 or F001 or K001 or D108” and AR3-3 and Galeterone and Prednisone, “B001 or F001 or K001 or D108” and AR3-4 and Galeterone and Prednisone, “B001 or F001 or K001 or D108” and AR1-1 and ODM201 and Prednisone, “B001 or F001 or K001 or D108” and AR1-2 and ODM201 and sone, “B001 or F001 or K001 or D108” and AR2-1 and ODM201 and Prednisone, “B001 or F001 or K 001 or D108” and AR2-2 and ODM201 and Prednisone, “B001 or F001 or K001 or D108” and AR2-3 and ODM201 and Prednisone, “ B001 or F001 or K001 or D108” and AR2-4 and ODM201 and Prednisone, “B001 or F001 or K00 1 or D108” and AR2-5 and ODM201 and Prednisone, “B001 or F001 or K001 or D108” and A R3-1 and ODM201 and Prednisone, “B001 or F001 or K 001 or D108” and AR3-2 and ODM201 and Prednisone, “B001 or F001 or K001 or D108” and AR3-3 and ODM201 and Prednisone, “ B001 or F001 or K001 or D108” and AR3-4 and ODM201 and Prednisone.

The combination above, illustrated by the combination of "B001 or F001 or K001 or D108" and AR1-1 and Abiraterone, represents the ation of B001 and AR1-1 and Abiraterone, the combination of F001 and AR1-1 and Abiraterone, the combination of K001 and AR1-1 and Abiraterone, and, the combination of D108 and AR1-1 and Abiraterone. According to this explanation, one skilled in the art can tand the meanings of the other combinations mentioned above.

Each of the components in the combination may be administered simultaneously or separately (eg, tially). When the components in the combination are administered simultaneously, the components in the ation may be uniformly mixed (ie, the mixture of components).

In the invention, the term nent” refers to a component in the combination of the ion, that is one of the eterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope compound, metabolite and prodrug thereof, the androgen receptor pathway modulator or the other therapeutic agents.

The present invention further es a pharmaceutical composition, sing the above combination and one or more of the pharmaceutically acceptable excipients.

In one aspect, the pharmaceutical composition of the invention may comprise one of the benzoheterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope compound, metabolite and prodrug thereof as mentioned above, the androgen receptor y modulator as mentioned above, and one or more of the pharmaceutically acceptable excipients.

In another aspect, the pharmaceutical composition of the invention may se one of the benzoheterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope compound, metabolite and prodrug thereof as mentioned above, the androgen receptor pathway modulator as mentioned above, the other therapeutic agents as mentioned above, and one or more of the pharmaceutically acceptable excipients.

The pharmaceutically acceptable excipients can be those widely used in drug manufacture field. The excipient is mainly used to provide a safe, stable and onalized pharmaceutical composition, and can also provide a method which makes the active ingredients dissolved at a desired rate after the subject receives administration or promotes the efficacy of absorbtion of the active ingredients after the subject is administered with the ition. The excipient can be an inert filler, or provide a certain function, such as stabilizing the overall pH value of the ition or preventing the degradation of the active ingredients of the composition. The pharmaceutically acceptable excipient may comprise one or more of the following excipients: binder, ding agent, emulsifier, t, filler, granulating agent, adhesive, disintegrating agent, lubricant, anti-adhesive agent, glidant, wetting agent, gelling agent, absorption retarder, dissolution inhibitor, reinforcing agent, adsorbent, buffer, ing agent, preservative, nt, flavoring agent and sweetening agent.

The methods of preparing pharmaceutical compositions known to people skilled in the art include but not limited to conventional mixing, dissolving, granulating, emulsifying, grinding, encapsulating, ing or lization. For example, the pharmaceutical composition of the present invention can be ed by mixing one of the benzoheterocyclic compound of a(I), the pharmaceutically acceptable salt, solvate, rph, co-crystal, stereoisomer, isotope compound, metabolite and prodrug thereof, the androgen receptor pathway modulator and the pharmaceutically acceptable excipient, or by mixing one or more of the benzoheterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, isomer, isotope compound, metabolite and prodrug f, the androgen receptor pathway modulator, the other therapeutic agents and the pharmaceutically acceptable excipient.

The pharmaceutical ition of the invention may be formulated into any form for administration, including injection (intravenous), mucosal, oral administration (solid and liquid preparation), inhalation, ocular administration, rectal administration, topical or parenteral (infusion, injection, implantation, subcutaneous, vein, artery, intramuscular) administration.

The pharmaceutical composition of the present invention can also be a controlled release or delayed release preparation. Examples of solid oral preparations e but not d to powder, capsule, caplet, soft capsule, pill and tablet. Examples of liquid preparations for oral or mucosal administration include but not limited to suspension, on, elixir and solution.

Examples of preparations for topical administration include but not limited to emulsion, gel, ointment, cream, patch, paste, foam, lotion, drops or serum preparation. Examples of preparations for eral stration include but not limited to injection solution, dry preparation which can be dissolved or ded in a pharmaceutically able carrier, injection suspension and injection emulsion. Examples of other suitable preparations of the pharmaceutical composition, include but not limited to eye drops and other lmic preparations; aerosol, such as nasal spray or inhalation; liquid dosage forms suitable for parenteral administration; suppository and pastille.

In another aspect, the ion provides a kit, comprising pharmaceutical composition A and pharmaceutical composition B; The pharmaceutical composition A comprises one of the benzoheterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, stal, stereoisomer, isotope compound, metabolite and prodrug thereof as ned above and one or more of the pharmaceutically acceptable excipients; The pharmaceutical composition B comprises the androgen receptor pathway modulator as mentioned above and one or more of the pharmaceutically acceptable excipients.

The kit may r comprise a pharmaceutical ition C, which comprises the other therapeutic agents as mentioned above and one or more of the pharmaceutically able ents.

Preferably, the benzoheterocyclic nd of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope nd, metabolite and prodrug thereof in the pharmaceutical composition A, the androgen receptor pathway modulator in the pharmaceutical composition B, the other eutic agents in the pharmaceutical composition C and the combination thereof are as mentioned above.

The pharmaceutical compositions in the kit may be administered simultaneously or separately (eg, sequentially).

In the kit, the term “pharmaceutically acceptable excipients” has the same definition as above.

In the ion, the term "active ingredient" refers to the active ingredient in the pharmaceutical composition or the kit of the invention, that is, one of the compound of formula(I), the ceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope compound, metabolite and prodrug thereof, the androgen receptor pathway modulator, the other therapeutic agents or the combination thereof.

The above combination, the above pharmaceutical composition or the above kit can be used for the prevention and/or treatment of prostate cancer. The prostate cancer is preferably tion-resistant prostate cancer.

In another aspect, the invention provides a use of the above one of the benzoheterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope compound, metabolite and prodrug thereof, in the manufacture of a medicament for the prevention and/or treatment of prostate cancer in ation with the above androgen receptor pathway modulator.

The invention provides a use of the above androgen receptor pathway modulator, in the manufacture of a medicament for the prevention and/or treatment of prostate cancer in combination with the above one of the benzoheterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, stal, stereoisomer, isotope nd, metabolite and prodrug thereof.

In another aspect, the ion provides a use of the above one of the benzoheterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope compound, metabolite and prodrug thereof, in the manufacture of a medicament for the prevention and/or treatment of prostate cancer in combination with the above androgen receptor pathway modulator and the above other therapeutic agents.

The invention provides a use of the above androgen receptor pathway modulator, in the manufacture of a medicament for the prevention and/or treatment of prostate cancer in combination with the above one of the eterocyclic compound of formula(I), the pharmaceutically able salt, e, polymorph, stal, stereoisomer, isotope compound, metabolite and prodrug thereof and the above other therapeutic agents.

The invention provides a use of the above other therapeutic agents, in the manufacture of a medicament for the prevention and/or ent of prostate cancer in combination with the above one of the benzoheterocyclic compound of formula(I), the pharmaceutically acceptable salt, e, rph, stal, stereoisomer, isotope compound, metabolite and prodrug thereof and the above androgen receptor pathway modulator.

In the use of the invention, the above one of the benzoheterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope compound, metabolite and g f, the above androgen receptor pathway modulator and the above other therapeutic agents may be administered simultaneously or separately (eg, sequentially).

In the use, the one of the benzoheterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope compound, metabolite and prodrug thereof, the androgen receptor pathway modulator, the other therapeutic agent and the combination thereof are as described above.

In another aspect, the invention provides a method of prevention and/or treatment of prostate cancer, comprising administration of a therapeutically or prophylactically effective amount of the above combination to the patients in need. The prostate cancer can be castrationresistant prostate cancer.

In an ment, the method of prevention and/or treatment of prostate cancer, comprises administration of a therapeutically or prophylactically ive amount of the above one of benzoheterocyclic nd of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope compound, metabolite and g f and a therapeutically or prophylactically effective amount of the above androgen receptor pathway modulator to the patients in need.

Wherein, the above one of the benzoheterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope compound, metabolite and prodrug thereof and the above en receptor pathway modulator may be administered simultaneously or separately (eg, sequentially).

In some embodiments of the invention, the method of prevention and/or treatment of prostate cancer ably comprises administration of a therapeutically or prophylactically effective amount of the above one of the benzoheterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope compound, metabolite and prodrug f, a therapeutically or prophylactically effective amount of the above en receptor pathway modulator and a therapeutically or prophylactically effective amount of the above other therapeutic agent to the patients in need.

Wherein ， the above one of the benzoheterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, rph, co-crystal, stereoisomer, isotope nd, metabolite and g thereof, the above androgen receptor pathway tor and the above other therapeutic agent may be administered simultaneously or separately (eg, sequentially).

In the method of prevention and/or treatment of prostate cancer, the one of thebenzoheterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, isomer, e compound, metabolite and prodrug f, the androgen receptor pathway modulator, the other therapeutic agent and the combination thereof are as described above.

In the combination, the pharmaceutical composition, the kit, the use or the method of prevention and/or treatment of prostate cancer of the invention, the mole ratio of the benzoheterocyclic compound of formula (I) and the androgen receptor pathway tor, can be selected in accordance with the conventional art, for example, 1:0.1-1:100，for example, 1:1- 1:50，for example, 1:1-1:10.

In the ation, the pharmaceutical composition, the kit, the use or the method of prevention and/or treatment of prostate cancer of the invention, when the other therapeutic agent is further comprised, the amount of the other therapeutic agent is not ularly limited, for example, the mole ratio of the other therapeutic agent and the androgen receptor pathway modulator can be 1:0.1-1:100，for example, 1:1-1:50，for example, 1:1-1:10.

In the combination, the pharmaceutical composition, the kit, the use or the method of prevention and/or ent of prostate cancer of the invention, the amount of the benzoheterocyclic compound of a (I) and the androgen receptor pathway modulator can be selected in accordance with the conventional art, for example, the amount of the benzoheterocyclic compound of a (I) can be 1-100µM，for example, 1-50µM，for example, 1-10µM; the amount of the androgen receptor pathway modulator can be M, for example, 1-100µM, for e, 1-10µM.

In the combination, the pharmaceutical composition, the kit, the use or the method of prevention and/or treatment of prostate cancer of the ion, when the other therapeutic agent is further comprised, the amount of the other therapeutic agent is not particularly limited, for example, the amount of the other therapeutic agent can be 1-300µM，for example, 1-100µM， for example, 1-10µM.

When each of the components in the combination of the invention is administered to a subject for the purpose of treating or preventing a disease, disorder or ion, each component in the combination may be administered by the same route or by a different route. The route of stration may be any route described herein, including but not limited to oral, inhalation, injection, lmic, mucosal, rectal, emulsion, liposome, long-acting implant or ned controlled release method. The specific route of administration will depend on the therapeutic agent itself and the preparation, as well as the disease, disorder or condition to be prevented or treated. According to the present disclosure, the skill level of an ordinary person skilled in the art is sufficient to determine the route of administration. Each of the components in the ation of the invention may be administered to the subject within a period of time istration period) followed by a period of no administration of the compound (nonadministration period). The administration period and non-administration period can be repeated for desired times. The desired length and times of the administration period or nonadministration period will depend on the type and/or severity of the disease, disorder or condition being treated or prevented, as well as the sex, age, weight, and other parameters (e.g. the individual subject’s biological, physical, and physiological , etc.) of the individual subject.

Each of the components in the combination of the invention may be administered simultaneously to the subject in a period of time and may also be stered to the subject sequentially in a period of time. According to the present sure, the skill level of an ordinary person skilled in the art is sufficient to ine the appropriate length and times of administration period and / or non-administration period.

The therapeutic method in the invention comprises administering each of the ents in the combination of the ion to a subject by any suitable methods, such as injection, mucosal, oral, inhalation, , rectal, long-acting implant, liposome, emulsion or sustained release process.

One skilled in that the art will understand that the eutically or prophylactically effective amount of each of the components or the active ingredients in the combination, pharmaceutical composition or the kit of the invention may vary with factors, for a specific subject, such as age, diet, health, etc., the symptom or disease to be treated or prevented, the ty of the disorder or condition, and the complications and types, and the preparations used etc. According to the disclosures in the invention, one skilled in the art can easily determine the desired therapeutically or prophylactically effective amount administered to the subject, so as to induce the desired biological or medical response in the subject.

In another embodiment, the combination, the pharmaceutical ition, the kit, the use or the method of tion and/or treatment of prostate cancer of the invention, the therapeutically or prophylactically effective amount of the androgen receptor pathway modulator or the other therapeutic agent may be lower than the effective amount when the compound of formula(I), the ceutically acceptable salt, solvate, polymorph, stal, stereoisomer, isotope compound, metabolite and prodrug thereof of the present invention is not administered.

In the invention, the amount of the nd administered, the therapeutically or prophylactically effective amount, the dosage, the starting dosage and the like are all referred to the amount of a specific compound, for e, a specific heterocyclic compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope compound, metabolite or prodrug thereof, a specific androgen receptor pathway modulator or a specific other therapeutic agent, rather than a combination of multiple compounds.

In the method of the ion, the therapeutically or lactically effective amount of the androgen receptor pathway modulator or the other therapeutic agent and the guidance for stration can be found in the patents and published patent applications cited herein, and Wells et al, eds., Pharmacotherapy Handbook, 2nd Edition, Appleton and Lange, Stamford, Conn. (2000); PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, Loma Linda, Calif. (2000) and other medical literatures.

In some embodiments, the therapeutically or prophylactically effective amount of the compound (herein referred as to one of the benzoheterocyclic compound of formula(I), the ceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope compound, metabolite and prodrug f, the androgen receptor pathway modulator, or the other therapeutic agent) administered to each subject is from about 0.005 to about 1000 mg/day, from about 0.01 to about 500 mg/day, from about 0.01 to about 250 mg/day, from about 0.01 to about 100 mg/day, from about 0.1 to about 100 mg/day, from about 0.5 to about 100 mg/day, from about 1 to about 100 , from about 0.01 to about 50 , from about 0.1 to about 50 mg/day, from about 0.5 to about 50 mg/day, from about 1 to about 50 mg/day, from about 0.02 to about 25 mg/day, or from about 0.05 to about 10 mg/day.

In some embodiments, the therapeutically or prophylactically effective amount (herein referred as to the eutically or lactically effective amount of the one of the eterocyclic compound of formula(I), the ceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotope compound, metabolite and prodrug thereof, the androgen receptor pathway modulator, or the other therapeutic agent) is about 0.01, about 0.05, about 0.1, about 0.2, about 0.3, about 0.4, about 0,5, about 0.6, about 0.8, about 1, about 2, about , about 10, about 15, about 20, about 25, about 30, about 40, about 45, about 50, About 60, about 70, about 80, about 90, about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700 About 750, about 800, about 850, about 900, or about 1000 mg/day/subject.

In any of the methods described herein, including but not limited to the above therapeutic methods, applications etc., the combination, the pharmaceutical composition or the kit according to the invention may be used alone or in combination with ultrasound y, radiation therapy (referred to as radiotherapy) or radioimmunotherapy etc., and may also be used in combination with one or more of other pharmacologically active therapeutic agents (hereinafter referred to as "other active agents"). The amount and type of other active agents will depend on the disease, disorder or condition to be treated or prevented; the severity of the disease, disorder or condition; factors of the t administrated with the composition, such as age, weight, physical conditions, etc.; the route of administration, and so on. According to the embodiments of the invention, the other active agent may be a natural, semi-synthetic or synthetic compound. In another embodiment, the other therapeutic agent may be a small le, such as a synthetic organic or inorganic molecule; or a larger molecule or biomolecule, such as a protein or nucleic acid with pharmacological activity. In another embodiment, the other therapeutic agent may be one or more of a chemotherapeutant, an antiangiogenic drug (also known as an angiogenesis inhibitor), an immunomodulatory agent, an immunotherapeutic agent, a monoclonal antibody, a polyclonal antibody, and a kinase inhibitor.

The chemotherapeutant therapeutic agent), is a chemically synthesized drug.

Currently, the chemotherapeutant is the main drug in the treatment of cancer and some autoimmune diseases, what commonly used are: epirubicin, bicin, daunorubicin, mitomycin, fluorouracil deoxynucleotides and so on.

The antiangiogenic drug inhibits angiogenesis by inhibiting pro-angiogenic growth factor, growth factor receptor or signaling pathway downstream etc., so as to inhibit the growth and metastasis of the tumors, and it mainly includes vascular elial growth inhibitor, receptor tyrosine kinase inhibitor, PI3K/AKT/mTOR pathway inhibitor, inant fusion n (e.g. aflibercept) acting on VEGF-A, VEGF-B and placental growth factor, recombinant human endostatin and so on.

The immunomodulatory agent is a drug which can enhance, promote and regulate immune functions and have a certain effect on immune dysfunction, some secondary immunodeficiency diseases and some malignant tumors. In accordance with the functions of the immunomodulatory agent, the immunomodulatory agent is mainly d into immunosuppressant and immunopotentiator. The former is used for anti-inflammatory, anti-autoimmune reactions, antiallergy , ransplant ion and anti-tumor, and the latter is for nfection, anti-allergy, and anti-tumor. Various kinds of drugs belong to immunosuppressant, including antimetabolic drugs(cyclosporin A, azathioprine, cyclophosphamide, methotrexate, mycophenolate, tacrolimus, mizoribine etc.), glucocorticoid, monoclonal antibody (anti-TNF-alpha/receptor, anti-IFN-γ, and anti-CD25 monoclonal antibody, etc.), cytokines IFN-β, IL-10 and TGF-β, chemicals(leflunomide and 5-HT3 receptor antagonist), non-steroid anti-inflammatory drugs, c acids, statins ipid drugs, HMG coenzyme A reductase inhibitor, plants (Tripterygium dii, t of Cordyceps sinensis FTY720, artemisinin and Parviline etc.) and other biological ts (cholera toxin B subunit, sNTB-A-Fc fusion protein, CMVIkappaBa carrier inhibitor and B7-HI inhibitor etc.). There are also various kinds of immunopotentiators, including cytokines(interferon α, interferon γ, thymic e, Thymopentin, G-CSF/GM-CSF, IL-2, IL-12, inant human erythropoietin, epidermal growth factor, chemokine intercellular adhesion molecule-1, vascular cell adhesion molecule-1, ctin, and other intercellular adhesion les, etc.), ical products [IVIG, transfer factor, immune riboncleic acid, bacteria and its extract lus Calmette Guerin and its extract, defatted and deactivated mycobacterium vaccine, other bacterial extracts, low calcium response V or V antigen LcrV，vibrio cholerae products Zot and mycobacterium etc.)], plant drugs (polysaccharides, saponins and other plant ingredients), chemicals (Levamisole, Tagamet, Pidotimod, NS-398 Imiquimod, Propagermanium and liposome etc.), micronutrients (vitamin A/C/D, trace elements iron, zinc, selenium) and others (macrolide antibiotics, aminophylline).

Immunotherapy refers to the modulation of the immune response of a subject to produce the desired therapeutic effect, the immunotherapeutic agent refers to a drug that when administered to a subject tes the immune system of the t so as to be sufficient to ultimately reduce the symptoms associated with an adverse immune response or ultimately reduce the symptoms caused by the increase of the required immune response.

The monoclonal dy refers to a highly m antibody, produced by a single B cell clone, targeting only a specific epitope.

The polyclonal antibody refers to different antibodies produced by using an antigen immune receptor that contains multiple antigenic determinants to stimulate multiple B cell clones in the body, ing multiple antigenic epitopes.

In biochemistry, kinases are enzymes that transfer ate groups from high-energy donor molecules (such as ATP) to specific target molecules (substrates); and this process is called phosphorylation; the kinase tor refers to a class of molecules that may bind with kinases and reduce their activity.

The other active agent includes but not limited to daratumumab, elotuzumab, palbociclib, panobinostat, nivolumab, lizumab, pemetrexed, topotecan, doxorubicin, bortezomib, gemcitabine, dacarbazine, biaxin, vincristine, azacitidine, CAR-T, rituximab, trastuzumab, PD- 1 inhibitor, PD-L1 inhibitor, HDAC inhibitor, androgen receptor pathway regulators other than the aforementioned androgen receptor pathway regulators, docetaxel, clofarabine injection, Ublituximab, romidepsin, BTK inhibitor, erythropoietin, bopag, minocycline and melphalan.

The term “androgen receptor pathway modulator” in the invention comprises androgen inhibitor, androgen or inhibitor, androgen biosynthesis inhibitor and other drugs that affect the androgen receptor pathway.

The term nes” are a class of chemicals that are produced by certain tissues of a normal body, and then diffuse into the blood, and are transported to other tissues in the body by blood circulation to exert l physiological functions. Hormonal compounds include synthetic or natural hormonal chemicals.

As used , when referring to a specific salt, composition, and excipient etc. as "pharmaceutically acceptable", it means that the salt, the composition, the excipient etc. are generally non-toxic, safe, and suitable for use in a subject, preferably a mammalian subject, more preferably a human subject.

The term “pharmaceutically acceptable salt” herein refers to a pharmaceutically acceptable organic or inorganic salt. Examples of the salt include but are not limited to: sulfate, citrate, acetate, e, chloride, bromide, iodide, nitrate, hydrosulfate, phosphate, acid phosphate, isonicotinic acid salt, lactate, salicylic acid salt, acid citrate, te, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, ate, e sulfonate, ethane sulfonate, benzene sulfonate, p-toluene sulfonate, and embonate (i.e. thylene-bis(2-hydroxynaphthoate)). The compounds of the present invention may form pharmaceutically acceptable salts with s amino acids. Suitable alkali salts include but are not limited to, aluminum salt, m salt, lithium salt, magnesium salt, potassium salt, sodium salt, zinc salt, bismuth salt and diethanolamine salt. For a review of the pharmaceutically acceptable salts, see ok of Pharmaceutical Salts: Properties, Selection, and Use (P. Heinrich Stahl and Camille G. Wermuth, ed., Wiley-VCH, 2002).

As used herein, the term “metabolite” refers to an active substance produced by changes in chemical structure that a drug molecule undergoes in vivo, the active substance is generally a derivative of the aforementioned drug molecule, and can also be chemically modified.

As used , the term “polymorph” refers to one or more crystal ures formed by the different arrangement of molecules in the lattice space when crystallized.

As used herein, the term “co-crystal” refers to a multi-component system comprising one or more API (active pharmaceutical ingredient) molecules and one or more object (or ligand) molecules. In the co-crystal, API molecules and object (or ligand) molecules exist as solids at room temperature when they are used as their pure form alone (in order to guish co-crystal from solvate or hydrate). From this particular definition, salts in which significant or complete proton exchange occurs n API molecules and guest molecules are excluded. In the tal , API and s interact through hydrogen bonds and other possible non-covalent interactions. It is noted that the co-crystal itself may form solvates, including hydrates. The object (or ligand) refers to other physiologically acceptable acids, bases or non-ionic compounds.

As used herein, the term “solvate” refers to a crystal form of the compound of a (I), the pharmaceutically able salt, polymorph, co-crystal, stereoisomer, isotopic compound, metabolite or prodrug thereof, which further comprises one or more solvent molecule(s) incorporated into the crystal structure. The solvate may include a stoichiometric amount or a non-stoichiometric amount of solvent, and the solvent molecule in the solvent may exist in an ordered or non-ordered arrangement. The solvate containing a oichiometric amount of solvent molecules may be obtained by the loss of at least one t molecule (but not all) from the solvate. In a ular embodiment, a solvate refers to a hydrate, which means the crystal of the compound further ses water molecules, with water molecules as the solvent.

As used herein, the term “prodrug” refers to a derivative of the compound comprising a biologically reactive onal group such that the biological reactive functional group can be cleaved from the compound or react in other ways to give the nd under biological conditions (in vivo or in vitro). Usually, the prodrug is inactive, or at least has lower ty than the compound itself, so that the compound exhibits its activity until it is cleaved from the biologically reactive functional group. The biologically reactive functional group can be hydrolyzed or oxidized under biological conditions to give the compound. For instance, the prodrug may contain a biologically hydrolysable group. Examples of the biologically hydrolysable group include but are not limited to: a biologically hydrolysable phosphate, a biologically hydrolysable ester, a biologically hydrolysable amide, a biologically hydrolysable carbonic ester, a biologically hydrolysable carbamate and a biologically hydrolysable ureide.

For a review of the prodrug, see, for example, J. Rautio et al., Nature Reviews Drug Discovery (2008) 7, 255-270 and gs: Challenges and Rewards (V. Stella et al. ed., Springer, 2007).

The compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, cocrystal , stereoisomer, isotope compound, lite or g thereof in the ation of the invention, may contain one or more tric centers (“stereoisomer”). As used herein, the term “stereoisomer” refers to all stereoisomers including enantiomers, diastereoisomers, epimers, endo-exo isomers, atropisomers, regioisomers, cis- and trans-isomers. The “stereoisomer” herein also includes "pure stereoisomer" and "enriched stereoisomer" or "racemic isomer" of the various aforementioned stereoisomers. These stereoisomers can be ed according to an asymmetric synthesis process, or separated, purified and enriched by a chiral separation process ding but not d to thin layer chromatography, rotating chromatography, column chromatography, gas chromatography, high pressure liquid chromatography, etc.), and can also be obtained through chiral separation by means of bonding cal binding etc.) or salifying (physical binding etc.) with other chiral compound(s). The term "pure stereoisomer" herein refers to a stereoisomer of the compound with the mass content of no less than 95% relative to other stereoisomers of the nd. The term "enriched stereoisomer" herein refers to a stereoisomer of the compound with the mass t of no less than 50% relative to other stereoisomers of the compound. The term "racemic isomer" herein refers to a stereoisomer of the compound with the mass content equal to that of other stereoisomers of the compound.

As used , D represents deuterium-enriched hydrogen, and H represents nondeuterium-enriched hydrogen. “Deuterium-enriched” compound means that abundance of deuterium at any relevant site in the compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, stal, stereoisomer, e compound, lite or prodrug thereof is greater than its natural abundance at that site (0.0156%). So, in the “deuteriumenriched” compounds, the abundance of deuterium at any of its related sites may be in the range of 0.0156% to 100%. An example of a process for obtaining deuterium-enriched compounds is to exchange hydrogen with deuterium or to synthesize the compound from deuterium-enriched starting material.

Based on the general knowledge in the art, the symbol H may be omitted in the terium-enriched site. “Non-deuterium enriched” refers to hydrogen in nature, i.e., in the form of isotopic mixture of H gen or protium), D (2H or deuterium) and T (3H or tritium).

The term “isotopic compound” used herein refers to the compound of formula (I), the pharmaceutically acceptable salt, the solvate, the polymorph, the stal, the stereoisomer, the isotopic nd, the metabolite or the prodrug thereof ning one or more atomic isotope(s) with natural or non-natural abundance. Atomic es with non-natural abundance include but are not limited to deuterium (2H or D), m (3H or T), iodine-125 (125I), phosphorus-32 (32P), carbon-13 (13C) or carbon-14 (14C). The aforementioned isotopic compound can also be used as a therapeutic or diagnostic agent (i.e., internal developing agent) or a research tool. All the isotopic variants of the compound of the present invention, whether radioactive or not, are included in the scope of the present invention.

The term “isotope enriched” used herein refers to the compound of formula(I), the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, metabolite or prodrug thereof containing one or more atomic isotope(s) with non-natural abundance. The term “isotope enriched” also refers to the compound of a (I), the pharmaceutically acceptable salt, the solvate, the polymorph, the co-crystal, the stereoisomer, the isotopic compound, the metabolite or the prodrug thereof containing at least one isotopic atom with non-natural abundance.

As used herein, the term "subject" or “patient” refers to any animal to be treated or treated with the compound or the composition according to the ments of the present invention, preferably mammal, and most preferably human. The term "mammal" used herein es any mammal. Examples of mammals include but not limited to cattle, horse, sheep, pig, cat, dog, mouse, rat, rabbit, guinea pig, monkey, human and the like, most preferably human. In an embodiment, the terms "treat" and ing" refers to an improvement, prevention or reversal of a disease or condition or at least one of identifiable symptoms thereof, such as treating cancer by reducing or stabilizing the symptoms of the cancer or the condition. In another embodiment, "treat" or "treating" refers to an improvement, prevention or al of at least one measurable body parameter of a e or condition which is being d, but may not be identified in mammal. However, in another ment, the term “treat” or “treating” refers to slowing the progression of a disease or condition, in al, such as stabilizing identifiable symptoms, or in physiological, such as stabilizing al parameters, or in both. In another embodiment, the term “treat” or “treating” refers to delaying the development of a disease or symptom.

In some embodiments, the combination, pharmaceutical composition or kit is administered for a prevention purpose. As used herein, "prevent" or "preventing" refers to a reduction in a risk of obtaining a given disease or condition. In a red embodiment, the designated combination, pharmaceutical ition or kit is administered for a tion purpose to a subject, such as a subject with family history or tendency of cancer or autoimmune disease.

As used , “therapeutically effective amount” refers to an amount of the compound or the composition (which is sought by researchers, veterinarians, physicians, or other clinicians) that can cause a biological or medical response in a tissue system, an animal or a person, which may include relieving symptoms of the disease or symptom which is being treated. In a preferred embodiment, the eutically effective amount is an amount which is enough to effectively treat, improve or prevent cancer, condition or undesirable angiogenesis.

The term “prophylactically effective amount” refers to an amount of the active compound or medicament (sought by researchers, narians, physicians or other clinicians) that can inhibit the development of a disease in a subject. A prophylactically effective amount of the compound refers to an amount of the eutic agent used alone or in combination with other active compound, which can provide a therapeutic benefit for treating or preventing the disease, condition or disorder.

Each preferred conditions aforementioned can be combined randomly without departing from the common knowledge in the art thereby forming various preferred embodiments of the present invention.

Unless otherwise specified, the singular form of the term used herein, "a" or "an", also includes a plural meaning.

Unless otherwise specified, the term "or" or "and" used herein refers to "and/or".

Various ations, articles, and patents are cited or described herein. The citation or description of these nces or the incorporation in their entirety or the discussion about them intends to illustrate the background of the present invention, but not to mean that the contents thereof form a part of the prior art of the present invention.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as ly understood by an ry person skilled in the art to which this invention belongs. Otherwise, the g of certain terms used herein has the meaning set forth in this description.

In the present invention, the structures of the other eutic agent are as follows: 1 (BAY-1841788) Galeterone (TOK-001) Abiraterone acetate Abiraterone Prednisone The reagents used in the invention are all commercially available. The compound of formula (I) and the androgen receptor pathway modulator in the invention may be prepared by people skilled in the art according to tic methods well known in the art, or readily synthesized according to the published literatures or patents, for example, the compound of formula (I) may be prepared according to the method published in 502 ， WO2008039489, WO2011100380 and so on; the androgen receptor pathway modulator may be ed according to the method published in WO2013087004, WO2014190895 , 029392, CN201010120494.9, WO2011029392, 036897 and so on.

The positive effect of the invention is that the combination of the invention can inhibit the growth of prostate cancer cells more effectively than the components used alone.

Examples The invention will be further illustrated by the ing examples, but it should not be constructed that the invention is limited to the scope of the es. The experimental methods that are not specified in details in the following examples are those according to conventional methods and ions, or according to the product manuals.

Effect embodiment 1 CTG cell proliferation assay In vitro test of the inhibition effect of the compound of formula (I) in combination with the androgen receptor pathway modulators or the compound of formula (I) in combination with the androgen receptor pathway modulators and the other therapeutic agent on the prostate cancer cell proliferation.

Inhibition effect of the compound B001, the above androgen receptor pathway modulators, the above other therapeutic agents, alone or in combination with each other on the prostate cancer cell proliferation were tested on Vcap cells (androgen receptor (+) prostate cancer cells) (ATCC, catalogue number CRL-2876). The specific experimental operation was as follows: 5×103 Vcap cells per well were inoculated into 96-well plates with transparent bottom and white wall (Corning, catalogue number 3) containing the specific medium, and were cultured in a 37 °C, 5% CO2 incubator for 24 hours. The tested compounds were prepared to a 150mM ng on with DMSO (Sigma, catalogue number ), diluted with culture medium to the desired concentrations (the final concentration of DMSO is 0.2%), and then added to each well, 2 wells/concentration, followed by being incubated in a 37 °C, 5% CO2 incubator for 5 days. The tested compounds were used alone or in ation. The other therapeutic agents were: Abiraterone acetate（Selleck, catalogue number S2246), Galeterone（Selleck, catalogue number , ODM-201 (Kangpu Biopharmaceuticals, Ltd.) or Prednisone (Selleck， gue number S1622). The concentration setting of each tested compound was shown in the ing tables of experimental results. After that, 100 μl of CellTiter-Glo® cell viability assay reagent (Promega, catalogue number G7570) was added to each well and mixed on a vibrator for 10 minutes to induce cell lysis. The 96-well plate was placed at room temperature for 10 minutes, so as to stabilize its luminescence signal. A white bottom ne was pasted on the bottom of the plate and the plate was tested using EnSpire. The data was processed by Graphpad/Prism and Calcusyn software to calculate the average cell proliferation inhibition rate or al rate for each compound, and the specific experimental results were shown in Table 1(contains two parts: Table 1 Part I and Table 1 Part II) and Table 2(contains two parts: Table 2 Part I and Table 2 Part II).

Table ains two parts: Table 1 Part I and Table 1 Part II) demonstrated the effects of the tested compound used alone or in combination with B001 or other therapeutic agents (including prednisone, Galeterone, abironate acetate, ODM-201) on the survival rate of Vcap cells. Because Table 1 contains a lot of information, Table 1 was divided into Table 1 Part I and Table 1 Part II.

Table ains two parts: Table 2 Part I and Table 1 Part II) demonstrated the effects of the tested compounds used in combination with B001 and other therapeutic agents (including prednisone, Galeterone, abironate acetate, 1) on the survival rate of Vcap cells. e Table 2 contains a lot of information, Table 2 was divided into Table 2 Part I and Table 2 Part II.

Table 1 Part I. Survival rate of Vcap cells： tested compound alone or in combination with B001 or other therapeutic agents (including prednisone, Galeterone, Abiraterone acetate, ODM-201) Tested Compound alone Tested Compound in combination with 1µM B001 (1, 10µM) 10µM 1µM 10µM 1µM AR2-2 57.9% 65.7% 41.974% 49.536% AR2-1 61.3% 74.0% 46.508% 54.401% AR2-3 57.5% 73.0% % 52.695% AR2-4 41.0% 73.5% 32.946% 53.165% AR3-1 56.5% 76.5% 41.310% % AR3-4 66.1% 77.0% 47.983% 52.699% AR3-2 62.8% 76.0% 42.044% % AR3-3 68.7% 83.5% 45.721% 59.220% AR2-5 71.2% 86.2% 58.564% 68.577% AR1-1 61.1% 74.5% 43.631% 51.992% AR1-2 60.9% 75.1% 42.006% 55.248% B001 74.1% 75.8% Prednisone 81.4% 91.8% Galeterone 33.4% 79.7% Abiraterone 54.1% 86.6% acetate ODM-201 67.6% 67.9% Table 1 Part II. Survival rate of Vcap cells： tested compound alone or in combination with B001 or other therapeutic agents (including prednisone, Galeterone, Abiraterone acetate, ODM-201) in combination in Tested in combination in with 1µM combinationwith Compou with 1µM combinationwith prednisone 1µM Abiraterone nd Galeterone 1µM 1 acetate 10µ 10µ 10µ 10µ 1µM 1µM 1µM 1µM M M M M 64.0 79.5 65.2 70.9 66.9 74.3 68.1 75.0 AR2-2 % % % % % % % % 58.5 77.7 58.3 71.8 58.3 69.2 61.4 72.9 AR2-1 % % % % % % % % 60.4 78.6 61.8 75.8 61.4 74.1 65.4 79.9 AR2-3 % % % % % % % % 42.3 75.9 38.4 72.4 42.4 71.2 42.3 74.1 AR2-4 % % % % % % % % 57.9 81.6 55.9 74.3 54.9 72.8 62.2 76.1 AR3-1 % % % % % % % % 69.1 82.2 68.1 76.1 64.5 73.6 68.4 78.3 AR3-4 % % % % % % % % 57.6 77.1 58.6 73.4 53.9 70.8 62.5 71.7 AR3-2 % % % % % % % % 60.3 82.3 62.2 78.0 57.5 75.0 64.5 74.0 AR3-3 % % % % % % % % 71.8 89.0 71.1 81.6 68.4 80.0 70.3 75.7 AR2-5 % % % % % % % % 62.2 79.9 66.6 73.8 60.6 71.1 64.2 68.4 AR1-1 % % % % % % % % 59.3 78.3 64.1 76.9 60.2 71.2 63.9 73.3 AR1-2 % % % % % % % % Notes: The results of Table 1 Part I and Table 1 Part II demonstrated that the effect of tested compound (AR2-2, AR2-1, AR2-3, AR2-4, AR3-1, AR3-4, AR3-2, AR3-3, AR2-5, AR1-1, AR1- 2) in combination with B001 was outstanding, for example, according to Table 1 Part I, the cell al rate was 65.7% when 1µM AR2-2 was used alone. The cell survival rate decreased to 49.536% when 1µM AR2-2 was used in combination with 1µM B001. However, the effect did not improve significantly when the tested compound (AR2-2, AR2-1, AR2-3, AR2-4, AR3- 1, AR3-4, AR3-2, AR3-3, AR2-5, AR1-1, AR1-2) was used in combination with the other therapeutic agents (including prednisone, Galeterone, erone acetate, ODM-201).

Table 2 Part I. Survival rate of Vcap cells: tested compound in combination with B001 and other therapeutic agents (including prednisone, Galeterone, Abiraterone e, ODM-201) in combination in combination in combination in combination with 1µM B001 with 1µM B001 Tested with 1µM B001 with 1µM B001 and 1µM and 1µM Compound and 1µM and 1µM ODMPrednisone Abiraterone Galeterone 201 acetate 10µM 1µM 10µM 1µM 10µM 1µM 10µM 1µM 37.3 50.5 38.7 43.6 38.8 47.4 41.8 47.4 AR2-2 % % % % % % % % 48.4 60.5 48.7 52.8 47.1 51.5 51.0 53.5 AR2-1 % % % % % % % % 40.7 51.7 40.1 45.2 40.6 47.0 42.3 47.4 AR2-3 % % % % % % % % 34.2 55.6 30.7 52.9 33.3 52.7 33.9 55.8 AR2-4 % % % % % % % % 40.8 57.9 38.2 48.4 39.2 49.6 44.0 51.4 AR3-1 % % % % % % % % 44.0 54.0 43.7 49.4 41.9 48.2 46.9 50.4 AR3-4 % % % % % % % % 39.3 56.4 40.5 47.9 38.4 46.9 44.6 50.3 AR3-2 % % % % % % % % 49.1 68.4 48.1 54.6 43.6 58.5 50.3 56.7 AR3-3 % % % % % % % % 56.1 67.2 62.7 68.6 60.0 66.6 58.6 57.3 AR2-5 % % % % % % % % 40.0 47.6 48.6 49.4 44.1 48.5 46.9 50.7 AR1-1 % % % % % % % % 43.1 55.1 38.0 49.9 35.5 47.3 41.3 46.8 AR1-2 % % % % % % % % Table 2 Part II. Survival rate of Vcap cells: tested compound in combination with B001 and other therapeutic agents (including prednisone, Galeterone, erone acetate, ODM-201) in combination with in combination with 1µM in combination with 1µM B001 and 1µM B001 and 1µM 1µM B001 and Tested Compound Prednisone and 1µM Prednisone and 1µM 1µM Prednisone Galeterone erone acetate and 1µM ODM-201 10µM 1µM 10µM 1µM 10µM 1µM AR2-2 35.2% 46.2% 35.6% 46.4% 40.5% 46.9% AR2-1 37.6% 47.3% 37.8% 43.7% 41.2% 42.9% AR2-3 51.9% 56.0% 51.9% 57.7% 54.5% 61.9% AR2-4 31.2% 54.8% 31.1% 49.4% 29.2% 50.9% AR3-1 37.9% 54.5% 37.5% 55.8% 42.6% 52.7% AR3-4 46.6% 52.0% 40.8% 46.8% 45.5% 46.4% AR3-2 45.7% 56.2% 43.4% 57.0% 49.8% 56.3% AR3-3 45.7% 59.0% 42.3% 57.0% 45.6% 48.4% AR2-5 58.4% 71.5% 57.3% 72.2% 59.6% 65.6% AR1-1 41.9% 54.0% 41.2% 49.5% 44.2% 46.7% AR1-2 44.4% 58.5% 44.5% 59.5% 50.8% 62.6% Notes: The results of Table 2 Part I and Table 2 Part II demonstrated that the effect of tested compound , AR2-1, AR2-3, AR2-4, AR3-1, AR3-4, AR3-2, AR3-3, AR2-5, AR1-1, AR1- 2) in combination with B001 was outstanding. When the tested compound was used in combination with B001 and the other therapeutic agent (including sone, Galeterone, Abiraterone acetate, ODM-201), the existence of the other therapeutic agent had no influence on the effect of the combination of the tested compound and B001. For example, the cell survival rate was 65.7% when 1µM AR2-2 was used alone (according to Table 1 Part I). The cell survival rate decreased to 49.536% when 1µM AR2-2 was used in combination with 1µM B001(according to Table 1 Part I). The cell survival rate was 50.5% when 1µM AR2-2 was used in combination with 1µM B001 and 1µM sone. The cell survival rate was 43.6% when 1µM AR2-2 was used in combination with 1µM B001 and 1µM Galeterone, The cell survival rate was 47.4% when 1µM AR2-2 was used in combination with 1µM B001 and 1µM Abiraterone acetate. The cell survival rate was 47.4% when 1µM AR2-2 was used in combination with 1µM B001 and 1µM ODM-201. The cell survival rate was 46.2% when 1µM AR2-2 was used in combination with 1µM B001 and 1µM Prednisone and 1µM Galeterone. The cell survival rate was 46.4% when 1µM AR2-2 was used in combination with 1µM B001 and 1µM Prednisone and 1µM Abiraterone acetate. The cell survival rate was 46.9% when 1µM AR2-2 was used in combination with 1µM B001 and 1µM Prednisone and 1µM ODM-201.

Although the ments of the invention were described above, it will be understood by people skilled in the art that these are just examples. Many changes and cations can be made to these embodiments without ing from the principle and e of the present invention. Therefore, the protection scope of the present invention is defined by the claims attached.

Claims (11)

What is d is:

1. A combination for the treatment of prostate cancer, comprising one of a benzoheterocyclic nd, a pharmaceutically acceptable salt, solvate, stal, stereoisomer, and isotope compound thereof, and an androgen receptor pathway modulator; wherein, the benzoheterocyclic compound is selected from the group consisting of: O O H NH O O O O H NH N O D NH D NH N O N O N O NH2 NH2 B001 B002 B003 NH2 B004 O O O O O O O O H NH H NH D NH D NH N O N O N O N O D D D D D D NH2 NH2 D NH2 NH2 B005 B006 B007 and B008 ; and the androgen receptor pathway modulator is selected from: O O O NC CD3 NC N CD3 S N S N NC CD3 H N H H F3C N N F F3C N N F F3C N N F O O O AR1-1 AR1-2 AR1-3 O O NC NC N D CD3 NC S N S N S N H H H F3C N N F O N N F F3C N N F D F O O O AR1-4 AR2-1 AR2-2 NC N S NC S CN NC O F3C N N F F3C N N F N N F3C N N F F F O O O AR2-3 AR2-4 AR2-5 O H NC NC N NC NH2 S NH S S O O F3C N N F F3C N N F3C N N F F F O O O AR2-6 AR2-7 AR2-8 H H H NC N NC N NC N S O S S O O O F3C N N F3C N N Cl N N F F F O O O AR2-9 AR2-10 AR2-11 NC NC NC S CN S CN S CN F3C N N F Cl N N F O N N F F F F O O O AR2-12 AR2-13 AR2-14 NC N NC S NC CN S S CN O N N F F3C N N O F3C N N F F F O O O AR2-15 AR2-16 AR2-17 NC NC N S CNNC S CN S F3C N N Cl N N F3C N N O F F F O O O AR2-18 AR2-19 AR2-20 OH N NC O S NC N NC N S N S F3C N N F F3C N N F O F3C N N F O F F F O O O AR2-21 AR2-22 AR2-23 NC S N NC N NC O S S F3C N N N F3C N N F O N N F F3C N N F F O O O AR2-24 AR2-25 AR2-26 NC S OH S NC S O NH2 NC S O OH N N F3C N N F3C N N F F3C N N F O O O AR2-27 AR3-1 AR3-2 NC O OH NC O OH S S OH NC O F3C N N F3C N N F3C N N F O O O O AR3-3 AR3-4 AR3-5 NC O NC O NC O OH S S S F3C N N F3C N N O F3C N N O O O O AR3-6 AR3-7 AR3-8 NC S O OH F3C N N AR3-9 .

2. The combination for the treatment of prostate cancer according to claim 1, n, the androgen receptor pathway modulator is one of the following compounds: AR1-1, AR1-2, AR2-1, AR2-2, AR2-3, AR2-4, AR2-5, AR3-1, AR3-2, AR3-3, AR3-4.

3. The combination for the treatment of te cancer according to claim 1, wherein, the combination of benzoheterocyclic compound and the androgen receptor pathway modulator is one of the following combinations: the combination of B001 and AR1-1, the combination of B001 and AR1-2, the combination of B001 and AR1-3, the combination of B001 and AR1- 4, the combination of B001 and AR2-1, the combination o f B001 and AR2-2, the combinat ion of B001 and AR2-3, the ation of B001 and AR2-4, the combination of B001 and AR2-5, the combination of B001 and AR2-6, the combination o f B001 and AR2-7, the combinat ion of B001 and AR2-8, the combination of B001 and AR2-9, the combination of B001 and , the combination of B001 and AR2-11, the combination of B001 and AR2-12, the combin ation of B001 and AR2- 13, the ation of B001 and AR 2-14, the combination of B001 and AR2-15, the combination of B001 and AR2-16, the combination of B001 and AR2 -17, the combination of B001 and AR2-18, the combination of B001 and AR2-19, the combin ation of B001 and AR2- 20, the combination of B001 and AR 2-21, the combination of B001 and AR2-22, the combination of B001 and , the combination of B001 and AR2 -24, the combination of B001 and AR2-25, the combination of B001 and AR2-26, the combin ation of B001 and AR2- 27, the combination of B001 and AR 3-1, the combination of B001 and AR3-2, the ation of B001 and AR3-3, the combina tion of B001 and AR3-4, the combi nation of B001 and AR3- 5, the combination of B001 and AR 3-6, the combination of B001 a nd AR3-7, the combination of B001 and AR3-8, or the com bination of B001 and AR3-9.

4. The combination for the treatment of prostate cancer according to claim 3, wherein, the combination of benzoheterocyclic compound and the androgen receptor pathway modulator is one of the following combinations: the combination of B001 and AR1-1, the ation of B001 and AR1-2, the combination of B001 and AR2-1, the combination of B001 and AR2- 2, the combination of B001 and AR2-3, the combination o f B001 and AR2-4, the combinat ion of B001 and AR2-5, the combination of B001 and AR3-1, the ation of B001 and AR3-2, the combination of B001 and AR3-3, and the combi nation of B001 and AR3-4.

5. The combination for the treatment of prostate cancer according to any one of claims 1-4, n, the combination further comprises other therapeutic agent selected from one of Abiraterone, Abiraterone acetate, rone, ODM201, Prednisone, Abiraterone and Prednisone, Abiraterone acetate and Prednisone, Galeterone and sone, and, ODM201 and Prednisone.

6. The combination for the treatment of prostate cancer according to claim 5, wherein, the combination of benzoheterocyclic compound, the androgen receptor pathway modulator and the other therapeutic agent is any one of the ing combinations: the combination of B001 and AR1- 1 and Abiraterone, the combinat ion of B001 and AR1-2 and Abiraterone, the combination of B001 and AR2-1 and Abirater one, the combination of B001 and AR2-2 and erone, the combination of B001 and AR2-3 an d Abiraterone, the combination of B001 and AR2-4 and Abiraterone, the combination of B001 and AR2-5 and Abiraterone, the combination of B001 and AR3-1 and Abiraterone, the combination of B001 and AR3-2 and Abiraterone, the combination of B001 and AR3-3 and Ab iraterone, the combination of B001 and AR3-4 and Abiraterone, the combination of B001 and AR1-1 and erone acetate, the combination of B001 and AR1-2 and Abiraterone acet ate, the combination of B001 and AR2-1 and Abiraterone acetate, the combination of B001 and AR2-2 and Abiraterone acetate, the combination of B001 and AR2-3 and Abiraterone acetate, the combination of B001 and AR2- 4 and erone acetate, the combination of B001 and AR2-5 an d Abiraterone acetate, the ation of B001 and AR3-1 and Abiraterone e, the comb ination of B001 and AR3-2 and Abiraterone acetate, the combination of B001 and AR3-3 and Abiraterone acetate, the combination of B001 and AR3-4 and Abiraterone acetate, the comb ination of B001 and AR1-1 and Galeterone, the combination of B001 and AR1-2 and Galeteron e, the combination of B001 and AR2-1 and Galeterone, the combination of B001 and AR2-2 and rone, the combination of B001 and AR2-3 and Galeterone, the combination o f B001 and AR2-4 and Galeterone, the combination of B001 and AR2-5 and Galeterone, t he combination of B001 and AR3-1 and rone, the combination of B001 and AR3-2 and Gal eterone, the combination of B001 and AR3-3 and Galeterone, the combination of B001 and AR3- 4 and Galeterone, the combination of B001 and AR1-1 and ODM201, the combination of B0 01 and AR1-2 and ODM201, the combination of B001 and AR2-1 and ODM201, the combi nation of B001 and AR2-2 and ODM201, the combinati on of B001 and AR2-3 and ODM201, the combination of B001 and AR2-4 and ODM201, the ation of B001 and AR2-5 an d ODM201, the combination of B001 and AR3-1 and ODM201, the combination of B0 01 and AR3-2 and ODM201, the ation of B001 and AR3-3 and ODM201, the combi nation of B001 and AR3-4 and ODM201, the combination of B001 and AR1-1 and s one, the combination of B001 and AR1-2 and Prednisone, the combination of B001 and AR2- 1 and Prednisone, the combination of B001 and AR2-2 and Prednisone, the combination o f B001 and AR2-3 and Prednisone, the combination of B001 and AR2-4 and Prednisone, t he combination of B001 and AR2-5 and Prednisone, the ation of B001 and AR3-1 and Pre dnisone, the combination of B001 and AR3-2 and Prednisone, the combination of B001 and AR3- 3 and Prednisone, the combination of B001 and AR3-4 and Prednisone, the combination o f B001 and AR1-1 and erone and Prednisone, the combination of B001 and AR1-2 a nd Abiraterone and Prednisone, the combination of B001 and AR2-1 and Abiraterone a nd Prednisone, the combination of B001 and AR2-2 and Abiraterone and Prednisone, the combination of B001 and AR2-3 and Abiraterone and Prednisone, the combination of B001 a nd AR2-4 and Abiraterone and Prednisone, the combination of B001 and AR2-5 and Abiratero ne and sone, the combination of B001 and AR3-1 and Abiraterone and Prednisone, the combination of B001 and AR3-2 and Abiraterone and Prednisone, the combination of B001 a nd AR3-3 and Abiraterone and Prednisone, the ation of B001 and AR3-4 and Abiratero ne and Prednisone, the combination of B001 and AR1-1 and Abiraterone acetate and Predn isone, the combination of B001 and AR1-2 and Abiraterone acetate and Prednisone, the comb ination of B001 and AR2-1 and Abiraterone acetate and sone, the combination of B001 and AR2-2 and Abiraterone acetate and Prednisone, the combination of B001 and AR2-3 and A rone acetate and Prednisone, the combination of B001 and AR2-4 and Abiraterone a cetate and Prednisone, the combination of B001 and AR2-5 and erone acetate and Predn isone, the combination of B001 and AR3-1 and Abiraterone acetate and Prednisone, the comb ination of B001 and AR3-2 and Abiraterone acetate and Prednisone, the combination of B001 and AR3-3 and Abiraterone acetate and Prednisone, the combination of B001 and AR3-4 and A biraterone e and Prednisone , the combination of B001 and AR1-1 and rone a nd Prednisone, the combination of B001 and AR1-2 and Galeterone and Prednisone, th e combination of B001 and AR2-1 and Galeterone and Prednisone, the combination of B001 an d AR2-2 and Galeterone and Prednisone, the combination of B001 and AR2-3 and Galeterone an d Prednisone, the combination of B001 and AR2-4 and Galeterone and Prednisone, th e combination of B001 and AR2-5 and Galeterone and Prednisone, the combination of B001 an d AR3-1 and Galeterone and Prednisone, the combination of B001 and AR3-2 and Galeterone an d Prednisone, the combination of B001 and AR3-3 and Galeterone and Prednisone, th e ation of B001 and AR3-4 and Galeterone and Prednisone, the ation of B001 an d AR1-1 and ODM201 and Prednisone, the combination of B001 and AR1-2 and ODM201 and sone, the ation of B001 and AR2-1 and ODM201 and Prednisone, the combination of B001 and AR2-2 and ODM201 and Prednisone, the combin ation of B001 and AR2-3 and OD M201 and Prednisone, the combination of B001 and AR2-4 and ODM201 and Prednisone, th e combination of B001 and AR2-5 and ODM201 and Prednisone, the combination of B001 an d AR3-1 and ODM201 and Prednisone, the ation of B001 and AR3-2 and ODM201 an d sone, the combination of B001 and AR3-3 and ODM201 and Prednisone, and th e combination of B001 and AR3-4 and ODM201 and Prednisone.

7. A pharmaceutical composition, comprising the combination ing to any one of claims 1-6 and one or more of the pharmaceutically acceptable excipients.

8. A kit, sing a pharmaceutical composition A and a pharmaceutical composition B; wherein, the pharmaceutical composition A comprises one of the benzoheterocyclic compound, the pharmaceutically acceptable salt, solvate, co-crystal, stereoisomer, and isotope compound thereof according to any one of claims 1-4 and one or more of the pharmaceutically acceptable excipients; the pharmaceutical composition B comprises the androgen receptor pathway modulator according to any one of claims 1-4 and one or more of the pharmaceutically acceptable excipients; preferably, the kit further comprises a pharmaceutical ition C, wherein, the pharmaceutical composition C comprises the other therapeutic agent according to claim 5 or 6 and one or more of the pharmaceutically acceptable excipients.

9. A use of the one of the benzoheterocyclic compound, the pharmaceutically acceptable salt, solvate, co-crystal, stereoisomer, and isotope compound thereof according to any one of claims 1-4 and the androgen receptor pathway modulator according to any one of claims 1-4, in the manufacture of a medicament for the prevention and/or treatment of prostate cancer.

10. A use of the combination of the benzoheterocyclic compound, the pharmaceutically acceptable salt, solvate, co-crystal, stereoisomer, and isotope compound thereof according to any one of claims 1-6 and the androgen receptor y modulator according to any one of claims 1-6 and the other therapeutic agent according to claim 5 or 6, in the manufacture of a medicament for the prevention and/or treatment of prostate cancer.

11. The use according to claim 9 or 10, n the te cancer is the castration-resistant te cancer.